Computational drug repositioning based on side-effects mined fromsocial media

PeerJ Computer Science

Volumn 2016, Issue 2, 2016, Pages

  Nugent, Timothy ^a   Plachouras, Vassilis ^a   Leidner, Jochen L ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

Adverse drug reaction; Drug repositioning; Drug repurposing; Graphical lasso; Graphical model; Inverse covariance estimation; Side effect; Social media

Indexed keywords

GRAPHIC METHODS; SOCIAL NETWORKING (ONLINE); SPEECH RECOGNITION;

ADVERSE DRUG REACTIONS; DRUG REPOSITIONING; GRAPHICAL LASSOS; GRAPHICAL MODEL; INVERSE COVARIANCE; REPURPOSING; SIDE EFFECT; SOCIAL MEDIA;

DRUG INTERACTIONS;

EID: 84987658065     PISSN: None     EISSN: 23765992     Source Type: Journal    
DOI: 10.7717/peerj-cs.46     Document Type: Article

References (91)

1. Allen MP. 1997. Covariance and linear independence. In: Understanding regression analysis. New York: Springer, 31-35.
2. Aronson JK. 2015. Meyer's side effects of drugs. 16th edition. Amsterdam: Elsevier. BackstromM,Mjorndal T, Dahlqvist R. 2004. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiology and Drug Safety 13(7):483-487 DOI 10.1002/pds.962.
3. Banerjee O, El Ghaoui L, D'Aspremont A. 2008. Model selection through sparse maximum likelihood estimation for multivariate Gaussian or binary data. The Journal of Machine Learning Research 9:485-516.
4. Barabasi AL, Gulbahce N, Loscalzo J. 2011. Network medicine: a network-based approach to human disease. Nature Reviews Genetics 12(1):56-68 DOI 10.1038/nrg2918.
5. Bento A, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, Krüger FA, Light Y,Mak L, McGlinchey S, Nowotka M, Papadatos G, Santos R, Overington JP. 2014. The ChEMBL bioactivity database: an update. Nucleic Acids Research 42(Database issue):D1083-D1090 DOI 10.1093/nar/gkt1031.
6. Bisgin H, Liu Z, Kelly R, Fang H, Xu X, Tong W. 2012. Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinformatics 13(Suppl 15):S6 DOI 10.1186/1471-2105-13-S15-S6.
7. BonekEYWatch. 2012. P2RY12 and its role in osteoclast activity and bone remodeling. Bonekey Reports 1:232 DOI 10.1038/bonekey.2012.232.
8. Boumans MJH, Thurlings RM, Yeo L, Scheel-Toellner D, Vos K, Gerlag DM, Tak PP. 2012. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Annals of the Rheumatic Diseases 71(1):108-113 DOI 10.1136/annrheumdis-2011-200198.
9. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. 2004. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27(11):2628-2635 DOI 10.2337/diacare.27.11.2628.
10. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. 2008. Drug target identification using side-effect similarity. Science 321(5886):263-266 DOI 10.1126/science.1158140.
11. Chee BW, Berlin R, Schatz B. 2011. Predicting adverse drug events from personal health messages. AMIA Annual Symposium Proceedings 2011:217-226.
12. Cheng F, Li W, Wu Z, Wang X, Zhang C, Li J, Liu G, Tang Y. 2013. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space. Journal of Chemical Information and Modeling 53(4):753-762 DOI 10.1021/ci400010x.
13. Danaher P, Wang P,Witten DM. 2014. The joint graphical lasso for inverse covariance estimation across multiple classes. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 76(2):373-397 DOI 10.1111/rssb.12033.
14. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP,Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ. 2011. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Science Translational Medicine 3(96):96ra76 DOI 10.1126/scitranslmed.3002648.
15. Duran-Frigola M, Aloy P. 2012. Recycling side-effects into clinical markers for drug repositioning. Genome Medicine 4(1):3 DOI 10.1186/gm302.
16. Emig D, Ivliev A, Pustovalova O, Lancashire L, Bureeva S, Nikolsky Y, Bessarabova M. 2013. Drug target prediction and repositioning using an integrated network-based approach. PLoS ONE 8(4):e60618 DOI 10.1371/journal.pone.0060618.
17. Evans WE, McLeod HL. 2003. Pharmacogenomics-drug disposition, drug targets, and side effects. New England Journal of Medicine 348(6):538-549 DOI 10.1056/NEJMra020526.
18. Feifel D. 2012. Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology 37(1):304-305 DOI 10.1038/npp.2011.184.
19. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. 2010. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biological Psychiatry 68(7):678-680 DOI 10.1016/j.biopsych.2010.04.039.
20. Feifel D, Reza T. 1999. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 141(1):93-98 DOI 10.1007/s002130050811.
21. Franke A,McGovern DPB, Barrett JC,Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A,Mathew CG,Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D,Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel J-F, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot J-P, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E,Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PCF, Torkvist L, Kullak-Ublick G,Wilson D,Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M,Weersma RK, Kugathasan S, Griffiths AM,Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. 2010. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics 42(12):1118-1125 DOI 10.1038/ng.717.
22. Freifeld CC, Brownstein JS,Menone CM, Bao W, Filice R, Kass-Hout T, Dasgupta N. 2014. Digital drug safety surveillance: monitoring pharmaceutical products in Twitter. Drug Safety 37(5):343-350 DOI 10.1007/s40264-014-0155-x.
23. Friedman J, Hastie T, Tibshirani R. 2008. Sparse inverse covariance estimation with the graphical lasso. Biostatistics 9(3):432-441 DOI 10.1093/biostatistics/kxm045.
24. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y,McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. 2012. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Research 40(Database issue):D1100-D1107 DOI 10.1093/nar/gkr777.
25. Ghofrani HA, Osterloh IH, Grimminger F. 2006. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery 5(8):689-702 DOI 10.1038/nrd2030.
26. Gimpl G,Wiegand V, Burger K, Fahrenholz F. 2002. Cholesterol and steroid hormones: modulators of oxytocin receptor function. Progress in Brain Research 139:43-55.
27. Ginn R, Pimpalkhute P, Nikfarjam A, Pakti A, O'Connor K, Sarker A, Smith K, Gonzalez G. 2014. Mining Twitter for adverse drug reaction mentions: a corpus and classification benchmark. In: Proceedings of the 4th workshop on building and evaluating resources for health and biomedical text processing, 1-8.
28. Hastie T, Tibshirani R, Wainwright M. 2015. Statistical learning with sparsity: the lasso and generalizations. Boca Raton: CRC Press.
29. Hazell L, Shakir SA. 2006. Under-reporting of adverse drug reactions: a systematic review. Drug Safety 29(5):385-396 DOI 10.2165/00002018-200629050-00003.
30. Hu G, Agarwal P. 2009. Human disease-drug network based on genomic expression profiles. PLoS ONE 4(8):e6536 DOI 10.1371/journal.pone.0006536.
31. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. 2013. Computational drug repositioning: from data to therapeutics. Clinical Pharmacology and Therapeutics 93(4):335-341 DOI 10.1038/clpt.2013.1.
32. Internet Live Stats. 2015. Twitter usage statistics. Available at http://www.internetlivestats.com/ twitter-statistics/ (accessed 30 April 2015).
33. Iorio F, Bosotti R, Scacheri E, Belcastro V,Mithbaokar P, Ferriero R,Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, Di Bernardo D. 2010. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proceedings of the National Academy of Sciences of the United States of America 107(33):14621-14626 DOI 10.1073/pnas.1000138107.
34. Jarvis L. 2006. Teaching an old drug new tricks. Chemical and Engineering News 84(7):54-55.
35. Jones N. 2009. Too few women in clinical trials Nature Epub ahead of print Jun 8 2009 DOI 10.1038/news.2009.549.
36. Jones DT, Buchan DW, Cozzetto D, Pontil M. 2012. PSICOV: precise structural contact prediction using sparse inverse covariance estimation on large multiple sequence alignments. Bioinformatics 28(2):184-190 DOI 10.1093/bioinformatics/btr638.
37. Jung SH, Park J-M, Moon E, Chung YI, Lee BD, Lee YM, Kim JH, Kim SY, Jeong HJ. 2014. Delay in the recovery of normal sleep-wake cycle after disruption of the light-dark cycle in mice: a bipolar disorder-prone animal model Psychiatry Investigation 11(4):487-491 DOI 10.4306/pi.2014.11.4.487.
38. Karimi S, Wang C, Metke-Jimenez A, Gaire R, Paris C. 2015. Text and data mining techniques in adverse drug reaction detection. ACM Computing Surveys 47(4): 56:1-56:39 DOI 10.1145/2719920.
39. Kohler S, Bauer S, Horn D, Robinson PN. 2008. Walking the interactome for prioritization of candidate disease genes. American Journal of Human Genetics 82(4):949-958 DOI 10.1016/j.ajhg.2008.02.013.
40. Kovács IA,Mizsei R, Csermely P. 2014. A unified data representation theory for network visualization, ordering and coarse-graining. ArXiv: Article 1409.8420.
41. Krauthammer M, Kaufmann CA, Gilliam TC, Rzhetsky A. 2004. Molecular triangulation: bridging linkage and molecular-network information for identifying candidate genes in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 101(42):15148-15153 DOI 10.1073/pnas.0404315101.
42. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. 2010. A side effect resource to capture phenotypic effects of drugs. Molecular Systems Biology 6:343 DOI 10.1038/msb.2009.98.
43. Ladenheim EE. 2015. Liraglutide and obesity: a review of the data so far. Drug Design, Development and Therapy 9:1867-1875 DOI 10.2147/DDDT.S58459.
44. Lamb J, Crawford ED, Peck D,Modell JW, Blat IC,Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H,Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. 2006. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929-1935 DOI 10.1126/science.1132939.
45. Leaman R,Wojtulewicz L, Sullivan R, Skariah A, Yang J, Gonzalez G. 2010. Towards internet-age pharmacovigilance: extracting adverse drug reactions from user posts to health-related social networks. In: Proceedings of the 2010 workshop on biomedical natural language processing. BioNLP '10. Stroudsburg: Association for Computational Linguistics, 117-125. Available at http://dl.acm.org/citation.cfm?id=1869961.1869976.
46. Ledoit O,Wolf M. 2003. Honey, I shrunk the sample covariance matrix. In: UPF economics and business working paper. 691.
47. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI. 2005. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30(10):1883-1894 DOI 10.1038/sj.npp.1300722.
48. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. 2001. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. Journal of Investigative Dermatology 117(6):1594-1600 DOI 10.1046/j.0022-202x.2001.01608.x.
49. Lopes CT, Franz M, Kazi F, Donaldson SL,Morris Q, Bader GD. 2010. Cytoscape Web: an interactive web-based network browser. Bioinformatics 26(18):2347-2348 DOI 10.1093/bioinformatics/btq430.
50. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. 2009. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Safety 32(1):19-31 DOI 10.2165/00002018- 200932010-00002.
51. Mazumder R, Hastie T. 2012. Exact covariance thresholding into connected components for large-scale graphical lasso. Journal of Machine Learning Research 13:781-794.
52. Meinshausen N, Bühlmann P. 2006. High-dimensional graphs and variable selection with the lasso. In: The annals of statistics. Beachwood: Institute of Mathematical Statistics, 1436-1462.
53. Mikolov T, Chen K, Corrado G, Dean J. 2013. Efficient estimation of word representations in vector space. ArXiv preprint. arXiv:1301.3781.
54. Nicolson SE, Nemeroff CB. 2007. Ziprasidone in the treatment of mania in bipolar disorder. Neuropsychiatric Disease and Treatment 3(6):823-834.
55. Nikfarjam A, Sarker A, O'Connor K, Ginn R, Gonzalez G. 2015. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. Journal of the American Medical Informatics Association 22(3):671-681 DOI 10.1093/jamia/ocu041.
56. Ogino K, Hatanaka K, Kawamura M, Ohno T, Harada Y. 2000. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. Pharmacology 61(4):244-250 DOI 10.1159/000028408.
57. Owen RT. 2006. Ramelteon: profile of a new sleep-promoting medication. Drugs Today 42(4):255-263 DOI 10.1358/dot.2006.42.4.970842.
58. Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL. 2011. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophrenia Research 132(1):50-53 DOI 10.1016/j.schres.2011.07.027.
59. Rainsford KD, Ying C, Smith FC. 1997. Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture. Journal of Pharmacy and Pharmacology 49(10):991-998 DOI 10.1111/j.2042-7158.1997.tb06030.x.
60. Ray SD. 2014. Side effects of drugs annual: a worldwide yearly survey of new data in adverse drug reactions. Vol. 36. Amsterdam: Elsevier Science, 2-651.
61. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. 1990. Osteopontin-a possible anchor of osteoclasts to bone. Proceedings of the National Academy of Sciences of the United States of America 87(12):4473-4475 DOI 10.1073/pnas.87.12.4473.
62. Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA,Maki PM. 2010. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophrenia Research 124(1-3):13-21 DOI 10.1016/j.schres.2010.09.014.
63. Sampathkumar H, Chen XW, Luo B. 2014. Mining adverse drug reactions from online healthcare forums using hidden Markov model. BMC Medical Informatics and Decision Making 14:91 DOI 10.1186/1472-6947-14-91.
64. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR,Mooser V. 2012. Use of genome-wide association studies for drug repositioning. Nature Biotechnology 30(4):317-320 DOI 10.1038/nbt.2151.
65. Sarker A, Gonzalez G. 2015. Portable automatic text classification for adverse drug reaction detection via multi-corpus training. Journal of Biomedical Informatics 53:196-207 DOI 10.1016/j.jbi.2014.11.002.
66. Schäfer J, Strimmer K. 2005. A shrinkage approach to large-scale covariance matrix estimation and implications for functional genomics. Statistical Applications in Genetics and Molecular Biology 4(1):Article 32 DOI 10.2202/1544-6115.1175.
67. Segura-Bedmar I, Martinez P, Revert R,Moreno-Schneider J. 2015. Exploring Spanish health social media for detecting drug effects. BMC Medical Informatics and Decision Making 15(Suppl 2):S6 DOI 10.1186/1472-6947-15-S2-S6.
68. Shorter K, Farjo NP, Picksley SM, Randall VA. 2008. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB Journal 22(6):1725-1736 DOI 10.1096/fj.07-099424.
69. Sirota M, Dudley JT, Kim J, Chiang AP,Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. 2011. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science Translational Medicine 3(96):96ra77 DOI 10.1126/scitranslmed.3001318.
70. Sustik MA, Calderhead B. 2012. GLASSOFAST: an efficient GLASSO implementation. UTCS Technical Report TR-12-29 2012. Austin: University of Texas at Austin. Available at http://apps. cs.utexas.edu/tech reports/reports/tr/TR-2105.pdf.
71. Tandon VR,Mahajan V, Khajuria V, Gillani Z. 2015. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian Journal of Pharmacology 47(1):65-71 DOI 10.4103/0253-7613.150344.
72. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. 2012. Data-driven prediction of drug effects and interactions. Science Translational Medicine 4(125):125ra31 DOI 10.1126/scitranslmed.3003377.
73. Thomson Reuters. 2012. Knowledge-based drug repositioning to drive R&D productivity. New York: The Thomson Reuters Corporation. Available at http://thomsonreuters.com/products/ip-science/ 04 038/drug-repositioning-cwp-en.pdf.
74. Thomson Reuters. 2015a. Thomson Reuters Cortellis Clinical Trials Intelligence. Available at http: //go.thomsonreuters.com/cti/ (accessed 30 April 2015).
75. Thomson Reuters. 2015b. Thomson ReutersWorld Drug Index. Available at http://thomsonreuters. com/en/products-services/pharma-life-sciences/life-science-research/world-drug-index.html/ (accessed 30 April 2015).
76. Tobinick EL. 2009. The value of drug repositioning in the current pharmaceutical market. Drug News & Perspectives 22(2):119-125 DOI 10.1358/dnp.2009.22.2.1343228. Twitter. 2015. Twitter.com. Available at http://twitter.com/ (accessed 30 April 2015). US Food and Drug Administraction. 2016. Drugs@FDA: FDA approved drug products. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 30 April 2015).
77. Twitter. 2015. Twitter.com. Available at http://twitter.com/ (accessed 30 April 2015). US Food and Drug Administraction. 2016. Drugs@FDA: FDA approved drug products. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 30 April 2015).
78. US Food and Drug Administraction. 2016. Drugs@FDA: FDA approved drug products. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 30 April 2015).
79. Vanunu O,Magger O, Ruppin E, Shlomi T, Sharan R. 2010. Associating genes and protein complexes with disease via network propagation. PLoS Computational Biology 6(1):e1000641 DOI 10.1371/journal.pcbi.1000641.
80. Vilar S, Uriarte E, Santana L, Lorberbaum T, Hripcsak G, Friedman C, Tatonetti NP. 2014. Similarity-based modeling in large-scale prediction of drug-drug interactions. Nature Protocols 9(9):2147-2163 DOI 10.1038/nprot.2014.151.
81. Wang H, Gu Q,Wei J, Cao Z, Liu Q. 2015. Mining drug-disease relationships as a complement to medical genetics-based drug repositioning: where a recommendation system meets genome-wide association studies. Clinical Pharmacology and Therapeutics 97(5):451-454 DOI 10.1002/cpt.82.
82. Wang ZY, Zhang HY. 2013. Rational drug repositioning by medical genetics. Nature Biotechnology 31(12):1080-1082 DOI 10.1038/nbt.2758.
83. Wang F, Zhang P, Cao N, Hu J, Sorrentino R. 2014. Exploring the associations between drug side-effects and therapeutic indications. Journal of Biomedical Informatics 51:15-23 DOI 10.1016/j.jbi.2014.03.014.
84. Wheater G, Hogan VE, Teng YKO, Tekstra J, Lafeber FP, Huizinga TWJ, Bijlsma JWJ, Francis RM, Tuck SP, Datta HK, Van Laar JM. 2011. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporosis International 22(12):3067-3072 DOI 10.1007/s00198-011-1607-0.
85. Wu Y-H, Ursinus J, Zhou J-N, Scheer FAJL, Ai-Min B, Jockers R, van Heerikhuize J, Swaab DF. 2013. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. Journal of Affective Disorders 148(2-3):357-367 DOI 10.1016/j.jad.2012.12.025.
86. Xie L, Kinnings S, Xie L, Bourne P. 2012. Predicting the polypharmacology of drugs: identifying new uses through chemoinformatics, structural informatics, and molecular modeling-based approaches. In: Barratt M, Frai D, eds. Drug repositioning: bringing new life to shelved assets and existing drugs. Hoboken: John Wiley & Sons.
87. Yang L, Agarwal P. 2011. Systematic drug repositioning based on clinical side-effects. PLoS ONE 6(12):e28025 DOI 10.1371/journal.pone.0028025.
88. Ye H, Liu Q,Wei J. 2014. Construction of drug network based on side effects and its application for drug repositioning. PLoS ONE 9(2):e87864 DOI 10.1371/journal.pone.0087864.
89. Zeng QT, Crowell J, Divita G, Roth L, Browne AC. 2005. Identifying consumer-friendly display (CFD) names for health concepts. In: AMIA annual symposium proceedings, 859-863. Available at http: //www.ncbi.nlm.nih.gov/pmc/articles/PMC1560732/.
90. Zhang J, Jiang K, Lv L,Wang H, Shen Z, Gao Z,Wang B, Yang Y, Ye Y,Wang S. 2015. Use of genome-wide association studies for cancer research and drug repositioning. PLoS ONE 10(3):e0116477 DOI 10.1371/journal.pone.0116477.
91. Zhang P,Wang F, Hu J, Sorrentino R. 2013. Exploring the relationship between drug side-effects and therapeutic indications. AMIA Annual Symposium Proceedings 2013:1568-1577.